相关实验视频
Updated: Jul 17, 2025

04:39
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
1.7K
30天甲基前尼索隆治疗细急性甲状腺炎的有效性和安全性:一项前性研究
Katica Bajuk Studen1,2, Simona Gaberšček1,2, Edvard Pirnat1
1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Endocrine connections
|September 7, 2023
概括
这项研究介绍了一种针对亚急性甲状腺炎的简短,有效的甲基普雷迪尼索隆方案,实现了81.4%的治愈率. 治疗间隔比目前的指导方针要短,对上腺功能不充分的安全性进行了评估.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于亚急性甲状腺炎的最佳皮质类固醇治疗方案尚未确定.
- 缩短皮质类固醇剂量可能导致症状复发,需要仔细规划治疗.
研究的目的:
- 评估30天甲基prednisolone协议对亚急性甲状腺炎的有效性和安全性.
- 为了评估这种治疗方案的上腺功能衰竭风险.
主要方法:
- 一项前性临床研究涉及59名被诊断患有亚急性甲状腺炎的患者.
- 患者接受了为期30天的甲基prednisolone (MPSL) 治疗方案,从每天24毫克开始,每5天逐渐减少4毫克.
- 在基线和随访时进行了短刺激上腺皮质增生激素 (ACTH) 测试,以评估上腺功能.
主要成果:
- 该方案导致了81.4%的治愈率 (48/59名患者).
- 七名患者 (12.3%) 患上了上腺功能不全,在这个组中观察到基线刺激皮质醇水平较低.
- 后勤模型确定了刺激皮质醇水平的最佳值,以预测治疗疗效和上腺功能.
结论:
- 评估的甲基普雷迪尼索隆方案对80%以上的亚急性甲状腺炎患者有效.
- 与目前的指导方针相比,该方案提供了较短的治疗间隔.
- 关于上腺功能衰竭的安全概况在研究参数范围内进行了评估.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Synthesis and Regulation of Thyroid Hormones
4.7K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.7K
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Antiasthma Drugs: Methylxanthines
266
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
266
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K

